Anxiety and depression are pathologies that affect human beings in many aspects of life,
including social life, productivity and health. Cannabidiol (CBD) is a constituent non …

The potential therapeutic use of some Cannabis sativa plant compounds has been attracting
great interest, especially for managing neuropsychiatric disorders due to the relative lack of …

The anxiolytic and antidepressant properties of cannabidiol (CBD) have been evaluated in
several studies. However, the molecular mechanisms involved in these actions remain …

Background: Panic disorder (PD) is a disabling psychiatry condition that affects
approximately 5% of the worldwide population. Currently, long-term selective serotonin …

Background and purpose: Cannabidiol (CBD) is a non‐psychotomimetic compound from
Cannabis sativa that induces anxiolytic‐and antipsychotic‐like effects in animal models …

Cannabidiol (CBD) is a compound of Cannabis sativa with relevant therapeutic potential in
several neuropsychiatric disorders including depression. CBD treatment has shown …

The pharmacological research on the Cannabis sativa-derived compounds has never
terminated. Among the phytocannabinoids without psychotropic effects, the prevalent one in …

The current study explores the therapeutic potential of Cannabidiol (CBD), a compound in
the Cannabis plant, using both sexes of 2 “depressive-like” genetic models, Wistar Kyoto …

Significant limitations with the currently available antidepressant treatment strategies have
inspired research on finding new and more efficient drugs to treat depression. Cannabidiol …

Background: Accumulating evidence suggests that cannabidiol (CBD) may be an effective
and safe anxiolytic agent and potentially also an antidepressant. Aim: The objective of this …